Clinical Trial

A Clinical Trial to Evaluate the Initial Safety and Efficacy of Repetitive BBB (Blood Brain Barrier) Disruption Using High Intensity Focused Ultrasound 'ExAblate 4000 Type 2.1' in Patients With Alzheimer's Disease

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2024 (before its estimated September 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
This clinical trial is designed to evaluate the initial safety and efficacy of opening the blood brain barrier (BBB) in patients with Alzheimer's disease using the ExAblate 4000 Type 2.1, a MR guided high-intensity focused ultrasound surgical device that disrupts brain tissue.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-19.
Trial Details
NCT Number NCT06474013
Lead Sponsor Korea University Anam Hospital
Conditions Alzheimer Disease
Enrollment 15 participants
Start Date 2024-09-01
Primary Completion 2024-09-30 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-21